Zacks Investment Research cut shares of Uniqure (NASDAQ:QURE) from a hold rating to a sell rating in a research note released on Friday morning.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
A number of other brokerages have also commented on QURE. HC Wainwright boosted their price target on Uniqure from $42.00 to $48.00 and gave the company a buy rating in a report on Monday, September 24th. BidaskClub downgraded Uniqure from a strong-buy rating to a buy rating in a research report on Friday, September 28th. Cantor Fitzgerald reaffirmed a buy rating and issued a $65.00 target price on shares of Uniqure in a research report on Thursday, November 15th. B. Riley lifted their target price on Uniqure from $50.00 to $72.00 and gave the company a buy rating in a research report on Friday, November 16th. Finally, Chardan Capital reaffirmed a buy rating and issued a $70.00 target price on shares of Uniqure in a research report on Monday, December 3rd. Two equities research analysts have rated the stock with a sell rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. Uniqure presently has an average rating of Buy and an average target price of $53.60.
Uniqure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.03. The company had revenue of $3.15 million for the quarter, compared to analyst estimates of $3.37 million. Uniqure had a negative return on equity of 58.49% and a negative net margin of 725.04%. On average, equities analysts expect that Uniqure will post -2.54 EPS for the current year.
In other news, Director Philip Astley-Sparke sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $30.39, for a total value of $151,950.00. Following the transaction, the director now owns 23,252 shares of the company’s stock, valued at $706,628.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Christian Klemt sold 5,739 shares of the company’s stock in a transaction that occurred on Thursday, January 3rd. The shares were sold at an average price of $27.91, for a total value of $160,175.49. Following the completion of the transaction, the insider now directly owns 40,000 shares in the company, valued at approximately $1,116,400. The disclosure for this sale can be found here. 1.56% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of QURE. Bank of New York Mellon Corp bought a new stake in Uniqure during the second quarter worth $628,000. Swiss National Bank acquired a new stake in Uniqure in the second quarter valued at $1,550,000. BlackRock Inc. increased its holdings in Uniqure by 6.7% in the second quarter. BlackRock Inc. now owns 464,426 shares of the biotechnology company’s stock valued at $17,555,000 after purchasing an additional 29,299 shares during the period. FMR LLC increased its holdings in Uniqure by 16.6% in the second quarter. FMR LLC now owns 3,694,681 shares of the biotechnology company’s stock valued at $139,659,000 after purchasing an additional 526,283 shares during the period. Finally, BlueMountain Capital Management LLC acquired a new stake in Uniqure in the second quarter valued at $383,000. 60.58% of the stock is currently owned by institutional investors.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Recommended Story: The Structure of a Futures Contract
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.